Hans G. Cruz
Adc Therapeutics (Switzerland)(CH)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Neuroscience and Neuropharmacology Research, HER2/EGFR in Cancer Research, Sleep and related disorders, Sleep and Wakefulness Research
Most-Cited Works
- → Bi-directional effects of GABAB receptor agonists on the mesolimbic dopamine system(2004)361 cited
- → RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area(2007)205 cited
- → Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study(2021)85 cited
- → Absence and Rescue of Morphine Withdrawal in GIRK/Kir3 Knock-out Mice(2008)76 cited
- → Evidence for a Centrally Located Gate in the Pore of a Serotonin-Gated Ion Channel(2002)75 cited
- → Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949(2016)70 cited
- → Dynamic role of kallikrein 6 in traumatic spinal cord injury(2006)66 cited
- → Zinc‐induced changes in ionic currents of clonal rat pancreatic β‐cells: activation of ATP‐sensitive K+ channels(2000)62 cited
- → Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma(2018)41 cited
- → Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study(2020)38 cited